British company developing stem cell therapy for stroke patients

Research surrounding stem cell therapy for stroke patients is making great strides. On Friday, April 17, British biotech company ReNeuron announced its Phase I clinical trial of a stem cell treatment for disabled stroke victims had concluded with promising results and no harm to any participants.

The researchers treated 11 disabled stroke patients with injections of neural stem cells to repair the areas of their brains where cells had been killed by the stroke. Level of disability due to stroke was measured on the National Institutes of Health Stroke Scale (NIHSS), with lower numbers representing less impairment.

The study found that all of the patients had improvements to their NIHSS scores after being treated with the neural stem cells. The median score for all patients at the beginning of the trial was seven, but by the end, it had decreased to five. The patients experienced significantly better neurological and limb function as a result of the stem cell treatment, positioning this treatment as potentially highly effective for stroke patients in the future.

CEO Olav Hellebø of ReNeuron said in a statement, "The data confirm the good safety profile of our CTX stem cell treatment in this setting and it is particularly gratifying to see that the functional improvements previously observed in the patients against baseline measurements have been maintained in long term follow up."

This follow-up will take the form of a longer-term Phase II study whose results are expected by the end of 2015.

If you're interested in learning more about how stem cell therapy can improve your life and help you age gracefully, contact the Longevity Centres of America today.